论文部分内容阅读
目的：观察维宁佳静脉滴注对危重病人合并下呼吸道感染的临床疗效。方法：选用危重病并下呼吸道感染病历９７例，随机分为两组：１组为维宁佳组４００ｍｇ，静脉滴注，每日２次；２组为头饱唑啉组３．０，静脉滴注，每日２次，疗程为７～１４天。观察感染控制效果及副作用发生情况。结果：维宁佳静脉滴注治疗５５例危重病人合并下呼吸道感染者，显效４８例，有效５例，总有效率为８７．３％，头孢唑啉静滴总有效率为５４．８％。两组差异非常显著（Ｐ＜０．００１）。结论：维宁佳是静脉滴注治疗危重病人合并下呼吸道感染的理想药物。
Objective: To observe the clinical effects of intravenous drip of Weiningjia on critically ill patients with lower respiratory tract infection. Methods: Ninety-seven cases of critically ill patients with lower respiratory tract infection were randomly divided into two groups: Group 1 was 400 mg of venlafaxin given intravenously twice daily; Group 2 was taupazoline 3.0, Instillation, 2 times a day, treatment for 7 to 14 days. Observe the infection control effect and side effects. Results: Weiningjia intravenous drip treatment of 55 cases of critically ill patients with lower respiratory tract infection, markedly effective in 48 cases, effective in 5 cases, the total effective rate was 87.3%, cefazolin intravenous infusion total effective rate was 54.8%. The difference between the two groups was significant (P <0.001). Conclusion: Weiningjia is an ideal drug for intravenous drip therapy in treating critically ill patients with lower respiratory tract infection.